Residency · Spokane, WA
Sponsored by Providence Sacred Heart Medical Center
Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson's Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study.
Neurology and therapy · 2023 · 115 citations · Jason Aldred
Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial.
The Lancet. Neurology · 2022 · 182 citations · Jason Aldred
Relevance of genetic testing in the gene-targeted trial era: the Rostock Parkinson's disease study.
Brain : a journal of neurology · 2024 · 89 citations · Jason Aldred
Preclinical and clinical evaluation of the LRRK2 inhibitor DNL201 for Parkinson's disease.
Science translational medicine · 2022 · 199 citations · Jason Aldred
Continuous subcutaneous foslevodopa/foscarbidopa infusion for the treatment of motor fluctuations in Parkinson's disease: Considerations for initiation and maintenance.
Clinical parkinsonism & related disorders · 2024 · 47 citations · Jason Aldred
YouTube as a source of information on fibromyalgia.
International journal of rheumatic diseases · 2021 · 102 citations · Tugba Unubol
Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression: The SURE-PD3 Randomized Clinical Trial.
JAMA · 2021 · 144 citations · Jason Aldred
Efficacy and Safety of Foslevodopa/Foscarbidopa Monotherapy in Patients with Parkinson's Disease.
Movement disorders clinical practice · 2026 · 8 citations · Jason Aldred